Actualités Apollomics Inc - APLM | Actions NASDAQ

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

FOSTER CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the...

Apollomics Announces Presentation at the 2024 BIO International Convention

FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”...

Apollomics Announces Private Placement Financing and Addition to Board of Directors

FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage...

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of...

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a...

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a...

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted...

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a...

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a...

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a...

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

FOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a...

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a...

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the...

Apollomics to Present at the 2024 Biotech Showcase

FOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a...

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

Treatment of NSCLC patients with MetExon14 skipping mutation with and without co-occurring MET amplification...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Apollomics Inc (APLM)

Votre Hub pour des idées et discussions en direct en temps réel

APLM Actualités

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apollomics Announces Presentation at the 2024 BIO International Convention

Apollomics Announces Private Placement Financing and Addition to Board of Directors

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Apollomics Inc (APLM) Actualités

Apollomics Inc (APLM)

Votre Hub pour des idées et discussions en direct en temps réel

APLM Actualités

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apollomics Announces Presentation at the 2024 BIO International Convention

Apollomics Announces Private Placement Financing and Addition to Board of Directors

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application